To establish a program to address sickle cell disease and other heritable hemoglobinopathies.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill, To establish a program to address sickle cell disease and other heritable hemoglobinopathies., changes federal law or congressional policy affecting health care providers and patients. The main policy domain is Healthcare, Education, Government Operations.
Who Benefits and How
health care providers and patients may benefit from new authority, funding, eligibility, regulatory clarity, or reduced risk created by the bill.
Who Bears the Burden and How
federal implementing agencies, health care providers and patients may take on implementation duties, reporting obligations, compliance costs, or oversight responsibilities.
Key Provisions
- Section id624c9ed78f2a42498515ded0965334d5: 1. Short title This Act may be cited as the Sickle Cell Disease Treatment Centers Act of 2024.
- Section id53797dfb0d44464c8684fc5ddefd8ddb: 2. Establishment of sickle cell disease and other heritable hemoglobinopathies treatment centers Subpart I of part D of title III of the Public Health Service...
- Section idfa750913185245a390b0984c55f6b6cf: 330Q. Sickle cell disease and other heritable hemoglobinopathies treatment centers In this section: The term community-based organization means a...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
This bill, To establish a program to address sickle cell disease and other heritable hemoglobinopathies., changes federal law or congressional policy affecting health care providers and patients.
Key Policy Areas
Healthcare, Education, Government Operations
Primary Purpose
This bill, To establish a program to address sickle cell disease and other heritable hemoglobinopathies., changes federal law or congressional policy affecting health care providers and patients.
Policy Domains
Whole bill
Identified Gains
- health care providers and patients
Identified Costs
- federal implementing agencies
- health care providers and patients
Sponsors
Legislative Progress
IntroducedMs. Lee of California (for herself, Ms. Adams, and Mr. …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "the_secretary"
- → The Secretary identified in the operative section
Key Definitions
Terms defined in this bill
any entity that is comprised of— a hub-and-spoke network that includes— a medical hub that is a hospital, clinic, or university health center
any entity that is comprised of— a hub-and-spoke network that includes— a medical hub that is a hospital, clinic, or university health center
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology